• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    $INTC
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RAAQ alert in real time by email
    • Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies.
    • De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications.

    IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (NASDAQ:RAAQ).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/

    From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer.

    From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer.

    Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level consistency across IQM's technology.

    "Ciesla's track record of scaling complex instrumentation platforms and building world-class R&D organizations makes him an exceptional addition to our leadership team," said Jan Goetz, CEO and Co-founder of IQM Quantum Computers. "As we accelerate our path toward fault-tolerant quantum computing, his experience integrating hardware and software systems at scale will be invaluable. I also want to thank Inés for her outstanding contributions over the years, and I am pleased she will continue to shape our technology roadmap in her new role."

    Ciesla is an accomplished innovator and product development leader with a proven track record and is an inventor of more than 100 patents and patent applications. He most recently served as Vice President of Engineering at 10x Genomics (NASDAQ:TXG) and previously held leadership roles at companies including Illumina (NASDAQ:ILMN) Lumentum (NASDAQ:JDSU), Intel (NASDAQ:INTC), and Tactus Technology.

    He also has significant board experience, serving on the Board of Directors of Lightwave Logic, Inc., (NASDAQ:LWLG) complemented by an academic background that includes a PhD in Physics from Heriot-Watt University.

    "IQM has established itself as an industry leader in quantum computing through a combination of technological excellence, real-world deployments, and disciplined execution. What attracted me to the company is its commitment to building production-grade quantum systems that customers can own, operate, and build value on — not just promises of what quantum could one day do," said Craig Ciesla.

    These appointments come as IQM continues to scale its technology roadmap and operations as a fully vertically integrated quantum computing company — operating its own chip factory and assembly line, and having sold 23 quantum computers to date, more than any other manufacturer.

    "Over the past years, I have seen first-hand how IQM has evolved from an ambitious deep-tech venture into a company delivering quantum computers to some of the world's leading research institutions and supercomputing centers," said De Vega. "I look forward to further contributing to the company's growth trajectory."

    Throughout her career, she has led a team responsible for developing and implementing quantum algorithms across a wide range of quantum computing applications, while developing advanced tools to tackle errors in quantum computers.

    Furthermore, she has been a researcher in several academic institutions, such as the Max Planck of Quantum Optics, the University of Ulm, and the Ludwig Maximilian University of Munich, where she is currently associated to the department of Theoretical Nanophysics.

    IQM is nearing its Nasdaq listing through a planned merger with Real Asset Acquisition Corp. (NASDAQ:RAAQ). The transaction has gained momentum since February, with an upsized PIPE of $146 million in early June after Finnish pension insurer Ilmarinen joined existing institutional investors.

    About IQM Quantum Computers

    IQM Quantum Computers is a global leader in superconducting quantum computers, delivering full-stack quantum computers and cloud platform access to research institutions, universities, high-performance computing centers, national laboratories and enterprises worldwide. IQM's on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018, headquartered in Finland with major operations in Munich, it has over 400 employees. IQM operates across Europe, Asia, and North America. IQM filed an F-4 registration statement with the SEC, which has since been declared effective, with the intention to become the first publicly listed European quantum company on Nasdaq Global Exchange in the U.S by merging with Real Asset Acquisition Corp. (NASDAQ:RAAQ).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260619693929/en/

    IQM Media contact:

    Email: press@meetiqm.com

    Mobile: +358 (0) 50 479 0845

    Get the next $RAAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAAQ
    $TXG
    $ILMN
    $INTC

    CompanyDatePrice TargetRatingAnalyst
    Intel Corporation
    $INTC
    6/11/2026$135.00Underperform → Buy
    BofA Securities
    Illumina Inc.
    $ILMN
    6/10/2026$185.00Neutral → Overweight
    Analyst
    Intel Corporation
    $INTC
    5/26/2026Outperform → Market Perform
    Northland Capital
    Intel Corporation
    $INTC
    5/18/2026$105.00 → $140.00Buy
    The Benchmark Company
    Intel Corporation
    $INTC
    5/18/2026$95.00 → $130.00Buy
    Citigroup
    Illumina Inc.
    $ILMN
    5/15/2026$170.00Outperform
    RBC Capital Mkts
    Illumina Inc.
    $ILMN
    5/14/2026$155.00Neutral → Outperform
    Daiwa Securities
    Intel Corporation
    $INTC
    4/24/2026$60.00 → $80.00Hold
    Jefferies
    More analyst ratings

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    EVP, CFO Zinsner David bought $249,985 worth of shares (5,882 units at $42.50), increasing direct ownership by 2% to 247,392 units (SEC Form 4)

    4 - INTEL CORP (0000050863) (Issuer)

    1/27/26 4:28:29 PM ET
    $INTC
    Semiconductors
    Technology

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term

    New research introduces a family of error-correcting codes that reduce qubit overhead by up to 1,000 times compared to today’s leading approach — without requiring any new hardware. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced a significant achievement in quantum error correction, using directional tile codes, marking a major step toward practical, large-scale fault-tolerant quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623243333/en/IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term The research, availab

    6/23/26 10:41:00 AM ET
    $RAAQ
    Blank Checks
    Finance

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare

    6/23/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform

    The collaboration will advance practical and scalable hybrid classical-quantum applications. This follows IQM's first on-premises quantum computer installation in the United States, at Oak Ridge National Laboratory. IQM has sold 23 quantum systems globally to date and intends to list on Nasdaq in the United States by mid 2026. Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/IQM Radiance quantum computer at HPE Discover Las Ve

    6/22/26 9:22:00 AM ET
    $RAAQ
    Blank Checks
    Finance

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saxonov Serge sold $1,033,269 worth of shares (30,000 units at $34.44) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,108,380 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    6/24/26 4:22:49 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/23/26 6:01:08 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Skovronsky Daniel

    3 - ILLUMINA, INC. (0001110803) (Issuer)

    6/23/26 5:56:51 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intel upgraded by BofA Securities with a new price target

    BofA Securities upgraded Intel from Underperform to Buy and set a new price target of $135.00

    6/11/26 8:00:56 AM ET
    $INTC
    Semiconductors
    Technology

    Illumina upgraded by Analyst with a new price target

    Analyst upgraded Illumina from Neutral to Overweight and set a new price target of $185.00

    6/10/26 8:16:12 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Intel downgraded by Northland Capital

    Northland Capital downgraded Intel from Outperform to Market Perform

    5/26/26 8:43:12 AM ET
    $INTC
    Semiconductors
    Technology

    $RAAQ
    $TXG
    $ILMN
    $INTC
    SEC Filings

    View All

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/26 9:08:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Real Asset Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Real Asset Acquisition Corp. (0002052161) (Filer)

    6/22/26 6:35:05 AM ET
    $RAAQ
    Blank Checks
    Finance

    Real Asset Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Real Asset Acquisition Corp. (0002052161) (Filer)

    6/17/26 4:05:28 PM ET
    $RAAQ
    Blank Checks
    Finance

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Financials

    Live finance-specific insights

    View All

    10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

    Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms. The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the l

    6/9/26 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports First Quarter 2026 Financial Results

    PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

    5/7/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results:Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%)GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases"Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Offic

    4/30/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Leadership Updates

    Live Leadership Updates

    View All

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare

    6/23/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Intel Announces Leadership Appointment at Intel Foundry to Accelerate Development and Manufacturing

    Intel Corporation today announced the appointment of Seok-Hee Lee as executive vice president of Intel Foundry, reporting directly to CEO Lip-Bu Tan. In this role, Lee will lead all advanced packaging, system integration, back-end technology development, and back-end manufacturing, strengthening Intel's ability to deliver differentiated, system-level innovation for customers. Seok-Hee Lee Appointed to Lead Advanced Packaging As part of the continued evolution of the Intel Foundry strategy, the company is establishing advanced packaging as a focused business with dedicated leadership. This reflects the growing importance and complexity of packaging as a key enabler of performance, power

    6/18/26 4:31:00 PM ET
    $INTC
    Semiconductors
    Technology

    $RAAQ
    $TXG
    $ILMN
    $INTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care